CytomX Therapeutics (CTMX) Cash & Equivalents (2014 - 2026)

CytomX Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• Quarterly Cash & Equivalents fell 39.44% year-over-year to $28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.8 million (down 39.44% YoY) and the FY2025 annual result came in at $12.7 million, down 66.71% from the prior year.
• Cash & Equivalents was $28.8 million for Q1 2026 at CytomX Therapeutics, up from $12.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $193.6 million in Q4 2022 and bottomed at $12.7 million in Q4 2025.
• A 5-year average of $62.9 million and a median of $43.2 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 91.13% — and 2024, when it soared 121.61%.
• CytomX Therapeutics' Cash & Equivalents stood at $193.6 million in 2022, then tumbled by 91.13% to $17.2 million in 2023, then surged by 121.61% to $38.1 million in 2024, then plunged by 66.71% to $12.7 million in 2025, then jumped by 127.58% to $28.8 million in 2026.
• Business Quant data shows CTMX's Cash & Equivalents at $28.8 million in Q1 2026, $12.7 million in Q4 2025, and $34.2 million in Q3 2025.